Revenue
2023
2024
2025
Entrada Therapeutics, Inc. (TRDA)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $25.4M | $210.8M | $129.0M | — | — | — |
| Research & development | $142.3M | $125.3M | $99.9M | $66.6M | $35.9M | $21.1M |
| Operating expenses | $183.3M | $163.8M | $132.2M | $97.2M | $51.1M | $26.7M |
| Operating income | −$157.9M | $47.0M | −$3.2M | −$97.2M | −$51.1M | −$26.7M |
| Net income | −$143.8M | $65.6M | −$6.7M | −$94.6M | −$51.2M | −$26.5M |
| Basic EPSper diluted share | -$3.47 | $1.76 | -$0.20 | -$3.02 | -$8.16 | -$24.00 |
| Diluted EPSper diluted share | -$3.47 | $1.68 | -$0.20 | -$3.02 | -$8.16 | -$24.00 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 20, 2026Form 4 | Zeiher Bernhardt GDirector | BuyCommon Stock · indirect | 5.0K | $5.86 | $29.3K | 5.0K |
| May 4, 2026Form 4 · 10b5-1 | Sethuraman NatarajanPresident, Research & Develop. | SellCommon Stock | 25.9K | $15.39 | $398.7K | 216.3K |
| May 4, 2026Form 4 · 10b5-1 | Dowden Nathan JPresident & COO | SellCommon Stock | 15.0K | $15.33 | $229.9K | 198.6K |
| Apr 1, 2026Form 4 · 10b5-1 | WENTWORTH KORY JAMESChief Financial Officer | SellCommon Stock | 2.5K | $12.95 | $32.4K | 119.0K |
| Mar 10, 2026Form 4 · 10b5-1 | Dowden Nathan JPresident & COO | SellCommon Stock | 11.9K | $13.05 | $155.2K | 198.6K |